Running Head: Novel Treatment of Lupus Erythematosis - Essay Example

Novel treatments for the disease include the use of anti-CD20 and anti-CD22 antibodies and uses of mAbs which interfere with the antibodies. Additionally, use of atacicept activator traditional methods inhibits the cell stimulation. The most effective drug in curing the disease is the new SLE, an anti-Blys antibody. This paper describes novel treatments of systemic Lupus Erythematosis including advantages over old regimens, side effects of treatments and success rate. Introduction Systemic Lupus Erythematosus is one of the many forms of Lupus (immune system diseases).

Being an autoimmune disease, this means that it attacks healthy tissues and other health organs. It can affect any part of the body, including the brain, blood vessels, heart, kidney, skin causing damage and inflammation of the joints. A large percentage of people who have lupus develop skin rashes, which are triggered by the sun, while others have lung and kidney problems. Since it affects the joints, it is considered as an arthritis rheumatic type of disease. Smith and Burns (2006), explain that autoimmune diseases are those diseases which occur when body tissues attacks their own system.

Individuals with Lupus produce abnormal antibodies that accompany inflammation of cells and affects body tissues anywhere in the body. Systematic Lupus can affect the heart, skin, kidney and nervous system. Leandro and Edward (2006) explain that when it only affects the skin, it is referred to as Lupus dermatitis, and if it affects the internal organs only, it is called Systemic Lupus Erythematosus. It mostly affects women from 20-45 years. The novel treatment for systemic lupus Erythematosus is managed by immunosuppressive drugs like cyclophosphamide, methotrexate and corticosteroids.

These drugs are mixed with hydroxychloroquines to fight the antibodies. Predominantly, Mofetil Mycophenolate is said to be more effective in patients with Lupus and has been licensed in most clinics for this indication. Leandro & Edward (2006), notes out that novel methods help reduce the antibodies formation in Systemic Lupus Erythematosus (SLE), which includes the use of deplete B-cells, Mabs and anti-CD20 and anti-CD22 antibodies among others. Some of the alternative approaches are atacicept, which is an activator transmembrane and modulator calcium ligand interactor, used as a protein fusion.

This helps in inhibiting the B-cells by binding Blys and a proliferation ligand. There is also molecule interaction costimulatory such as CD40 ligand with a combination of mAbs and other soluble antigens that have been used as one of therapy strategies for SLE. However, the promising drug for SLE is the Belimumab from GlaxoSmith, which acts as an anti-Blys antibody, as a trial with the drug meeting its endpoints. Some of the advantages of novel treatment over the old regimens are patients using shorter periods and low doses of cyclophosphamide drugs during treatment.

This type of immunosuppressive drug is used in treating SLE and reduces the side effects of the drugs without efficacy sacrificial. In addition, less immunosuppressive drugs that are less toxic in the body act as an alternative for treating patients. The old regimen also combines various treatments with a number of agents to produce a single drug for patients. Side effects of the treatments include kidney problems, stomach bleeding and high-risk of heart problems. This results from a patient taking Anti malarial drugs as one of the novel treatment of Lupus.

In addition, when an SLE takes